Susquehanna International Group’s Celgene Corporation Contingent Value Rights CELGZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q3
Sell
-75,435
Closed -$47K 11311
2019
Q2
$47K Buy
75,435
+472
+0.6% +$339 ﹤0.01% 9855
2019
Q1
$81K Sell
74,963
-35,498
-32% -$34.7K ﹤0.01% 8327
2018
Q4
$50K Buy
+110,461
New +$101K ﹤0.01% 8485
2018
Q3
Sell
-31,196
Closed -$11K 10930
2018
Q2
$11K Buy
31,196
+17,715
+131% +$5.33K ﹤0.01% 9466
2018
Q1
$5K Sell
13,481
-16,246
-55% -$10.6K ﹤0.01% 9200
2017
Q4
$29K Buy
+29,727
New +$34.1K ﹤0.01% 9031
2016
Q4
Sell
-15,486
Closed -$16K 10649
2016
Q3
$16K Sell
15,486
-343
-2% -$414 ﹤0.01% 8265
2016
Q2
$23K Buy
+15,829
New +$20.4K ﹤0.01% 8366

Other funds holding CELGZ

Susquehanna International Group's CELGZ Position: Q3 2019 in Review

Susquehanna International Group sold out of Celgene Corporation Contingent Value Rights (CELGZ) in Q3 2019, closing a stake of 75,435 shares — an estimated $47K sold.

Susquehanna International Group first reported a position in CELGZ in Q2 2016 and held it in 8 quarters. The position peaked at $81K in Q1 2019. 24 funds tracked by Wall St. Rank hold CELGZ as of Q3 2019.

  • Susquehanna International Group reported no remaining Celgene Corporation Contingent Value Rights position as of Q3 2019 after selling out during the quarter.
  • Susquehanna International Group sold 75,435 Celgene Corporation Contingent Value Rights shares in Q3 2019, an estimated $47K.
  • Susquehanna International Group first reported a position in Celgene Corporation Contingent Value Rights in Q2 2016 and held it in 8 quarters.
  • Susquehanna International Group's Celgene Corporation Contingent Value Rights position peaked at $81K in Q1 2019.
  • 24 funds tracked by Wall St. Rank held Celgene Corporation Contingent Value Rights as of Q3 2019.

Based on Susquehanna International Group's 13F filing for Q3 2019, filed 14 Nov 2019.